Oppenheimer Forecasts Strong Price Appreciation for TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group (NASDAQ:TMDX) had its price target lifted by research analysts at Oppenheimer from $150.00 to $175.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 30.04% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. Piper Sandler raised their price objective on TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday. Needham & Company LLC increased their target price on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday. Morgan Stanley lifted their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday. Finally, Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $150.67.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $134.57 on Wednesday. The firm has a 50-day moving average of $133.45 and a two-hundred day moving average of $126.31. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 7.13. The stock has a market cap of $4.62 billion, a P/E ratio of 27.46 and a beta of 2.06. TransMedics Group has a 1-year low of $62.07 and a 1-year high of $156.00.

Insiders Place Their Bets

In other news, Director David Weill sold 5,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the sale, the director owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. The trade was a 29.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the sale, the chief financial officer owned 15,064 shares in the company, valued at approximately $2,103,235.68. This trade represents a 5.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Whittier Trust Co. of Nevada Inc. grew its position in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after buying an additional 206 shares during the last quarter. Salomon & Ludwin LLC bought a new stake in shares of TransMedics Group during the 3rd quarter worth $28,000. Harvest Fund Management Co. Ltd bought a new stake in shares of TransMedics Group during the 3rd quarter worth $29,000. Optiver Holding B.V. grew its holdings in shares of TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares during the last quarter. Finally, Allworth Financial LP raised its position in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Q4 results beat expectations — Q4 EPS of $0.57 and ~32% revenue growth topped estimates; management raised 2026 revenue guidance to roughly 20–25%, supporting near‑term top‑line momentum. TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates
• Positive Sentiment: Analysts raised targets and ratings — Several firms bumped price targets (Oppenheimer to $175/outperform; Needham to $174/buy; Piper Sandler to $160/overweight; JPMorgan to $149/neutral), signaling institutional confidence in the company’s growth trajectory and helping push the stock higher. TransMedics Group (NASDAQ:TMDX) Given New $175.00 Price Target at Oppenheimer TransMedics Group (NASDAQ:TMDX) Given New $174.00 Price Target at Needham & Company LLC TransMedics Group (NASDAQ:TMDX) Given New $160.00 Price Target at Piper Sandler TransMedics Group (NASDAQ:TMDX) Given New $149.00 Price Target at JPMorgan Chase & Co.
• Positive Sentiment: Visibility on growth initiatives — Management highlighted advancing OCS (organ care system) programs and European expansion as drivers of the 20–25% 2026 revenue target, giving investors a clearer multi‑year growth story. TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
• Neutral Sentiment: Earnings materials and call available — The company released its Q4 presentation and the full earnings‑call transcript, useful for parsing unit trends, margins, and cadence of commercialization. TransMedics Group, Inc. 2025 Q4 – Results – Earnings Call Presentation TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Investor commentary and outlook pieces are circulating — Market write‑ups are debating whether the strong one‑year +79% move leaves room for more upside or signals late‑cycle profit taking. Is It Too Late To Consider TransMedics Group (TMDX) After Its 79% One-Year Surge?
• Negative Sentiment: Valuation and momentum risk — The stock’s run and a P/E near the mid‑20s leave vulnerability to multiple contraction or profit‑taking if execution or cadence disappoints; investors should weigh growth guidance against elevated expectations.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.